New dosing strategy tested for common eye disease
NCT ID NCT04679935
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 31 times
Summary
This study tested two different schedules of the eye injection brolucizumab in 52 adults with wet age-related macular degeneration (AMD) whose vision was not fully controlled by previous treatment. The goal was to see which dosing plan works better and is safer over 52 weeks. Participants received the same drug but at different intervals, and researchers measured changes in vision and treatment needs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Regensburg, Bavaria, 93053, Germany
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60549, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Bonn, 53105, Germany
-
Novartis Investigative Site
Düsseldorf, 40225, Germany
-
Novartis Investigative Site
Göttingen, 37075, Germany
-
Novartis Investigative Site
Hanover, 30625, Germany
-
Novartis Investigative Site
Homburg, 66421, Germany
-
Novartis Investigative Site
Leipzig, 04103, Germany
-
Novartis Investigative Site
Lübeck, 23538, Germany
-
Novartis Investigative Site
Magdeburg, 39120, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
-
Novartis Investigative Site
Marburg, 35039, Germany
-
Novartis Investigative Site
Münster, 48149, Germany
-
Novartis Investigative Site
Neubrandenburg, 17036, Germany
-
Novartis Investigative Site
Ulm, 89075, Germany
-
Novartis Investigative Site
Lausanne, CHE, 1000, Switzerland
-
Novartis Investigative Site
Bern, 3007, Switzerland
-
Novartis Investigative Site
Zurich, 8063, Switzerland
Conditions
Explore the condition pages connected to this study.